TearScience, Inc.

TearScience, Inc.

TearScience, Inc.

Date Founded



5151 McCrimmon Parkway Suite 250 MORRISVILLE NC 27560

Type of Company


Employees (Worldwide)

101 - 250


Medical Products & Equipment
Hospitals & Patient Services
Medical Support Services
Electrical Products

Company Description

TearScience, Inc. diagnoses and treats meibomian gland dysfunction. It offers Lipiflow, Lipiscan, and Lipiview. The company was founded by Donald R. Korb and Timothy R. Willis in 2005 and is headquartered in Morrisville, NC.

Contact Data
Trying to get in touch with decision makers at TearScience, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder & Chief Technical Officer

Chief Financial Officer

Director, Supply Chain & Manufacturing Pilot Operations

Vice President, International Sales



Compliance Coordinator

Vice President Marketing


Regional Sales Manager

Board of Directors

Member, Board of Directors at TearScience, Inc.

Paths to TearScience, Inc.
Potential Connections via
Relationship Science
TearScience, Inc.
Recent Transactions
Details Hidden

Johnson & Johnson, Abbott Medical Optics, Inc. purchase TearScience, Inc. from General Catalyst LLC, Spray Venture Partners LP, De Novo Ventures, Quaker Partners Management LP, Essex Woodlands Management, Inc., Patricia Industries, Inc.

Details Hidden

TearScience, Inc. raised money in a private placement transaction

Details Hidden

TearScience, Inc. raised money in a private placement transaction

Advisors & Consultants
Medical Advisor

Medical Director at Midwest Surgical Services, Inc.

Scientific Advisor

Lead Optometric Advisor at OcuMedic, Inc.

Medical Advisor

Vice President-President-Elect at American Society of Cataract and Refractive Surgery

Non-Profit Donations & Grants
Details Hidden

De Novo Ventures focuses on investments in medical device and biotechnology companies. They invest across all stages of a company's development from early- to late-stage. De Novo Ventures invests throughout the US, but has a preference for investing in companies located in the Western US.

Details Hidden

Healthcare Royalty Management invests primarily in commercial stage healthcare companies, pharmaceutical, biotechnology and products through the purchase of traditional passive royalties, the creation of synthetic royalties, structured debt and equity instruments. The firm focus on healthcare companies and products across a broad range of therapeutic areas predominately in the US and European Union. They targets investments of $20 million to $200 million. They provides financing capital to assist in the transfer of product and execution risk, finance new development opportunities, acquire new products or technologies, fund additional capital needs and monetize product royalties.

Details Hidden

Essex Woodlands Health Ventures focuses on diversified healthcare investing. They invest in the pharmaceutical, biotechnology, medical device, services and information technology sectors. They tend to focus on early-stage investments, but may also make later-stage investments including mature venture, growth equity and PIPE investment opportunities.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by TearScience, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of TearScience, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and TearScience, Inc..